[191 Pages Report] The Continuous Glucose Monitoring Systems Market size was estimated at USD 5.54 billion in 2023 and expected to reach USD 6.21 billion in 2024, at a CAGR 12.37% to reach USD 12.55 billion by 2030.
Continuous Glucose Monitoring Systems (CGMS) are advanced medical devices designed to provide real-time glucose readings at regular intervals, typically every few minutes, 24/7. These systems comprise a small sensor that transmits the data wirelessly to a display device, which could be a dedicated receiver, a smartphone, or a smartwatch, enabling the user to monitor their glucose levels without the requirement of traditional fingerstick blood tests. The growing preponderance of diabetes across the globe and the rising awareness of the benefits of continuous glucose monitoring over traditional blood glucose monitoring are driving the market growth. However, devices' high prices and lack of uniform reimbursement can limit market penetration. Inaccuracies in glucose readings due to device calibration issues or interference from external factors also pose a challenge. Furthermore, leveraging big data and advanced analytics to improve predictive capabilities, personalization, and clinical outcomes creates potential opportunities for market growth.
Integrated insulin pumps are devices that deliver insulin automatically based on the set basal rate and work in conjunction with continuous glucose monitoring (CGM) systems. They adjust the insulin delivery based on real-time glucose readings. This feature greatly contributes to the seamless management of blood glucose levels in diabetes patients, especially useful for those with intensive insulin therapy needs or those with Type 1 diabetes. Sensors are a crucial part of CGM systems, as they are the components that measure levels of glucose in the interstitial fluid beneath the skin. CGM sensors typically require changing every 7 to 14 days, depending on the model. Patients who desire minimal intrusion and longer wear times prefer sensors with extended life spans. The transmitter is the part of the CGM system that sends real-time glucose data from the sensor to a receiver and smart device. The receiver is the device that displays the glucose data. Some patients prioritize a system that allows the use of their own smartphone as a receiver, whereas others prefer a dedicated device if they are not comfortable using smart devices.
Continuous Glucose Monitoring (CGM) systems are crucial for the adult population, especially those diagnosed with Type 1 or Type 2 diabetes. Adults require consistent and accurate monitoring of their blood glucose levels to manage their condition effectively and to prevent acute and long-term complications associated with diabetes. CGM systems for children are designed with special considerations for size, sensitivity, and ease of use, owing to the unique physiological and lifestyle requirements of the pediatric population. These devices help parents and caregivers monitor and manage their child's diabetes more effectively, providing peace of mind and improved quality of life.
Patients with Type 1 diabetes rely on external insulin because of the autoimmune destruction of the insulin-producing beta cells in the pancreas. Continuous Glucose Monitoring (CGM) systems for this group provide convenience and crucial tools for the management of glucose levels. These patients need real-time data to adjust insulin doses accurately. CGM systems offer significant advantages over traditional blood glucose monitoring, providing detailed insights into glucose trends, which results in better glycemic control and reduction of hypoglycemia risk. Type 2 diabetes patients might not always require insulin but still need to monitor their glucose levels, especially if they are on sulfonylureas and meglitinides, which increase the risk of hypoglycemia. CGM for Type 2 diabetes is geared towards lifestyle management, including diet and exercise, alongside medication. The use of CGM is progressively becoming more common in this group as the technology becomes more affordable and as evidence mounts that it can help improve glycemic control in non-insulin-treated patients.
Diagnostic centers and clinics represent a significant segment for the deployment of Continuous Glucose Monitoring (CGM) systems. These facilities often serve as the initial point of contact for patients experiencing symptoms of diabetes and for those who require ongoing monitoring for their diagnosed condition. Home healthcare represents a rapidly growing segment for CGM systems, as an increasing number of patients with diabetes prefer to manage their condition in the comfort of their own homes. These devices offer convenience and allow for continuous monitoring without the need to visit a healthcare provider frequently. Intensive Care Units (ICUs) are critical settings wherein patients require constant and close monitoring, including for their glucose levels. CGM systems in ICUs must be highly reliable and capable of integrating with other monitoring equipment to ensure a holistic view of a patient's health status.
The Americas, led by the United States and Canada, show a strong market for CGM systems, aided by higher purchasing power and well-established healthcare systems implementing the latest technologies. The United States & Canada are prominent in CGM technology, with numerous companies researching and developing new systems, evident from a high number of patents filed in this domain. Consumers in the United States have shown an inclination towards maintaining healthy lifestyles, integrating personal health technology with everyday living. There is significant investment and insurance coverage that promotes the use of CGM systems, making them more accessible to the population. European Union countries demonstrate a robust demand for CGM systems, broadly supported by widespread awareness, a push for lifestyle management of diabetes, and favorable insurance reimbursement scenarios. The European Union’s medical device sector is tightly regulated, ensuring high standards of product quality and safety. Countries including Germany, France, and the UK are leaders in the adoption of CGM systems. The Middle East, particularly the Gulf Cooperation Council (GCC) countries, has high per capita healthcare spending and is rapidly adopting advanced technologies in healthcare. Asia Pacific is undergoing a surge in the demand for CGM systems due to the increasing prevalence of diabetes and heightened awareness about the disease. The rising popularity of wearable technology for health monitoring indicates a broad consumer need for convenient and non-intrusive healthcare devices in the APAC region.
The FPNV Positioning Matrix is pivotal in evaluating the Continuous Glucose Monitoring Systems Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Glucose Monitoring Systems Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Sibionics obtains CE Mark for GS1 continuous glucose monitoring system
Sibionics, a Chinese medical technology startup, has received the CE Mark for its pioneering GS1 Continuous Glucose Monitoring (CGM) system, signaling the green light for the system's sale and usage across the European market. This certification confirms the GS1 CGM's compliance with stringent EU standards for quality, safety, and performance, which are essential for consumer trust. [Published On: 2023-11-02]
Dexcom targets Americans with new CGM aimed at non-insulin-using diabetics
Dexcom is set to revolutionize the continuous glucose monitoring (CGM) market by unveiling a new device tailored for Americans living with Type 2 diabetes who do not require insulin therapy. This strategic move addresses a critical gap, highlighted by Dexcom's research, which is that a mere 5% of this demographic currently utilizes CGM technology. [Published On: 2023-06-26]
U.S. FDA Clears Abbott's Freestyle Libre 2 and Freestyle Libre 3 Sensors for Integration with Automated Insulin Delivery Systems
Abbott has announced FDA clearance for its next-generation FreeStyle Libre 2 and FreeStyle Libre 3 iCGM sensors, paving the way for their seamless integration with automated insulin delivery (AID) systems. Expanding their versatility, the improved sensors offer additional convenience and support for diabetes management by pairing them with insulin pumps to adjust insulin delivery automatically based on continuously monitored glucose levels. [Published On: 2023-03-06]
The report delves into recent significant developments in the Continuous Glucose Monitoring Systems Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l, Abbott Laboratories, AgaMatrix Inc. by I-Sens Inc., Ascensia Diabetes Care Holdings AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, NXP Semiconductors N.V., Senseonics Holdings Inc., Sibionics, STMicroelectronics N.V., Tandem Diabetes Care, Inc., Texas Instruments Incorporated, and Ypsomed Holding AG.
This research report categorizes the Continuous Glucose Monitoring Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Component
- Integrated Insulin Pumps
- Sensors
- Transmitters & Receivers
- Demographics
- Adult Population
- Children Population
- Patient Type
- Type 1 Diabetes
- Type 2 Diabetes
- End User
- Diagnostic Centers & Clinics
- Home Healthcare
- ICUs
- Distribution Channel
- Institutional Sales
- Retail Sales
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Continuous Glucose Monitoring Systems Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Glucose Monitoring Systems Market?
- What are the technology trends and regulatory frameworks in the Continuous Glucose Monitoring Systems Market?
- What is the market share of the leading vendors in the Continuous Glucose Monitoring Systems Market?
- Which modes and strategic moves are suitable for entering the Continuous Glucose Monitoring Systems Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Continuous Glucose Monitoring Systems Market, by Component
- Continuous Glucose Monitoring Systems Market, by Demographics
- Continuous Glucose Monitoring Systems Market, by Patient Type
- Continuous Glucose Monitoring Systems Market, by End User
- Continuous Glucose Monitoring Systems Market, by Distribution Channel
- Americas Continuous Glucose Monitoring Systems Market
- Asia-Pacific Continuous Glucose Monitoring Systems Market
- Europe, Middle East & Africa Continuous Glucose Monitoring Systems Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 26]
- List of Tables [Total: 460]
- List of Companies Mentioned [Total: 19]
CGM systems are advanced medical devices that record and display an individual's glucose levels continuously, especially for people with diabetes. These systems can measure glucose levels in real-time or at set intervals throughout the day, and the data is usually transmitted to a receiver or a mobile application, providing users with updates on glucose levels and trends. Unlike traditional blood glucose monitoring systems, CGMs provide more accurate and near-real-time measurements of glucose levels, making them incredibly useful for tracking blood sugar trends, identifying patterns in glucose levels, and making treatment decisions.
There are several CGM systems on the market today, such as standalone CGMs, which come with both a monitor and a transmitter, and integrated CGMs, which connect to insulin pumps. Some CGMs also come in adhesive patches attached to the skin and can transmit data to a smart device.
CGMs have several advantages that make them an essential tool in diabetes management. One significant advantage is that they help people with diabetes detect hypoglycemia or hyperglycemia early. This early warning allows for prompt intervention, reducing the risk of high and low blood sugar complications. Also, CGMs can provide insights into glucose patterns, assisting clinicians and patients in making informed decisions on diet, lifestyle, and medication.
Despite the advantages, CGMs have some disadvantages, including high cost, technical complexity, and discomfort associated with the insertion of the sensor and the need to calibrate the device. However, these limitations are gradually being addressed as technology advances, making CGMs more accessible and comfortable.
Continuous Glucose Monitoring Systems have revolutionized diabetes management, providing insights into glucose levels that were previously unattainable through traditional blood glucose monitoring. With more advanced and user-friendly CGM devices making their way into the market, there is no doubt that they will become a more common feature in diabetes management, potentially reducing the incidence of complications related to high and low blood sugar.
- How big is the Continuous Glucose Monitoring Systems Market?
- What is the Continuous Glucose Monitoring Systems Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?